3 research outputs found
Recommended from our members
Determinants of female career competencies: The role of familysupportive supervisor and career mobility
This study aims to explore the determinants of female career competencies. Two constructs—family-supportive supervisor and career mobility are developed as the determinants, while career satisfaction is developed as the outcome. The relationship between each constructs will be examined by structural equation modeling. The findings of this study will help hotel operators to practice strategic human resources management and encourage female hotel managers to improve their career competencies
Recommended from our members
A comparative study of the job perceptions of hospitality and tourism staff in China
This study explores the job perceptions of hotel staff and tour guides. It aims to discover more about their skills, attitudes and career plans, and gain comparative insights that will help to develop human resources within these areas of work. The findings reveal that both hospitality and tourism sector in China are faced with a shortage of human resources with an appropriate level of education and of suitably high quality. Oral communication is identified the most important skill identified as a need, followed by professional and ethical standards as well as team work and leadership qualities. Ideas vary considerably with respect to the relative importance of skills within the two work areas. Compared with hotel staff, tour guides in China show lower job loyalty, in part because of low social status and poor opportunities for career progress. This paper concludes that it is essential for Chinese government agencies at a national and provincial level to practice effective and sector-sensitive measures to attract, train , retain and develop appropriate talent in order to meet the needs and challenge of the international tourism industry
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
Background: Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin and angiotensin receptor antagonist being examined in an ongoing phase 3 trial in adults with IgA nephropathy. We report the prespecified interim analysis of the primary proteinuria efficacy endpoint, and safety. Methods: PROTECT is an international, randomised, double-blind, active-controlled study, being conducted in 134 clinical practice sites in 18 countries. The study examines sparsentan versus irbesartan in adults (aged ≥18 years) with biopsy-proven IgA nephropathy and proteinuria of 1·0 g/day or higher despite maximised renin-angiotensin system inhibitor treatment for at least 12 weeks. Participants were randomly assigned in a 1:1 ratio to receive sparsentan 400 mg once daily or irbesartan 300 mg once daily, stratified by estimated glomerular filtration rate at screening (30 to 1·75 g/day). The primary efficacy endpoint was change from baseline to week 36 in urine protein-creatinine ratio based on a 24-h urine sample, assessed using mixed model repeated measures. Treatment-emergent adverse events (TEAEs) were safety endpoints. All endpoints were examined in all participants who received at least one dose of randomised treatment. The study is ongoing and is registered with ClinicalTrials.gov, NCT03762850. Findings: Between Dec 20, 2018, and May 26, 2021, 404 participants were randomly assigned to sparsentan (n=202) or irbesartan (n=202) and received treatment. At week 36, the geometric least squares mean percent change from baseline in urine protein-creatinine ratio was statistically significantly greater in the sparsentan group (-49·8%) than the irbesartan group (-15·1%), resulting in a between-group relative reduction of 41% (least squares mean ratio=0·59; 95% CI 0·51-0·69; p<0·0001). TEAEs with sparsentan were similar to irbesartan. There were no cases of severe oedema, heart failure, hepatotoxicity, or oedema-related discontinuations. Bodyweight changes from baseline were not different between the sparsentan and irbesartan groups. Interpretation: Once-daily treatment with sparsentan produced meaningful reduction in proteinuria compared with irbesartan in adults with IgA nephropathy. Safety of sparsentan was similar to irbesartan. Future analyses after completion of the 2-year double-blind period will show whether these beneficial effects translate into a long-term nephroprotective potential of sparsentan. Funding: Travere Therapeutics